Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

Immunicum's cell therapy misses survival endpoint in Phase II RCC trial
Immunicum AB (SSE:IMMU) lost SEK1.46 (14%) to SEK8.86 after reporting that ilixadencel plus Sutent sunitinib from

Read the full 267 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE